Anthony O. Caggiano

Dr. Caggiano is broad-based therapeutic development executive with experience across a range of disease indications, including neurological disorders. Prior to joining Cognition Therapeutics, Dr. Caggiano was acting president and chief medical officer of Constant Pharmaceuticals and Aeromics, Inc., clinical-stage companies respectively developing candidates for central nervous system disorders and cerebral edema following ischemic stroke. Earlier, as senior vice president of research and development at Acorda Therapeutics, he oversaw a staff managing clinical and preclinical research and development programs in multiple sclerosis, spinal cord injury and other neurological disorders.